• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Zimmer Biomet Highlights Diverse Portfolio of Orthopedic & Musculoskeletal Innovations at AAOS 2025 Annual Meeting

    3/10/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care
    Get the next $ZBH alert in real time by email

    Booth Spotlights Comprehensive Hip Portfolio, Newly Launched Knee and Upper Extremities Reconstructive Technologies, Including Recently Cleared Persona® Revision SoluTion™ Femur, and Debut of ZBX™ Ambulatory Surgery Center Solutions

    WARSAW, Ind., March 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting its diverse portfolio of orthopedic and musculoskeletal innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting being held March 10-14 in San Diego. During the meeting, the Company's booth will prominently feature its comprehensive hip portfolio, anchored by the new Z1™ Triple-Taper Femoral Hip System, along with the latest technologies for knee and upper extremity reconstruction and key components from its robotic solutions. In addition, Zimmer Biomet is debuting ZBX™, its new Ambulatory Surgery Center (ASC) offering to surgeons and institutions looking to expand their orthopedic footprint.

    (PRNewsfoto/Zimmer Biomet Holdings, Inc.)

    "I am thrilled to showcase the collective strength and broad range of our musculoskeletal portfolio, including the introduction of several recently cleared technologies, at this year's annual AAOS meeting," said Ivan Tornos, President and Chief Executive Officer at Zimmer Biomet. "We are in the midst of one of the largest innovation cycles in our company's history. Our broad hip reconstruction portfolio combined with our comprehensive knee portfolio with constructs designed to safeguard against cement and metal sensitivities, our bone-preserving stemless shoulder and now an enhanced suite of ASC solutions, squarely position us at the forefront of delivering customer-centric innovations to improve efficiency and overall patient outcomes."

    The highlights at the Zimmer Biomet booth (#3129) include:

    Hip Reconstruction Technologies

    • Z1™ Femoral Hip System, a triple-taper design with expansive innovations within a more comprehensive system, providing more solutions to treat more patients.
    • HAMMR® Automated Hip Impaction System, designed to address surgeon strain, fatigue and repetitive motion associated with traditional mallet use during bone preparation and device implantation.
    • OrthoGrid Hip AI®, an AI-powered, fluoroscopy-based technology that provides direct anterior (DA) hip surgeons with intuitive and instantaneous intra-operative tools to assist surgeons in achieving the desired surgical outcomes for component positioning.1
    • HipInsight™ System, the first FDA-cleared mixed reality system for hip navigation offers intuitive, intra-operative guidance that leverages the Microsoft HoloLens 2 (mixed reality headset) to help visualize and guide accurate2 acetabular component placement and alignment in real-time.

    Knee Reconstruction Technologies

    • Persona® Revision SoluTion™ Femur, a newly cleared revision knee implant component, part of the comprehensive Persona Revision Knee System, offering an alternative to cobalt-chrome (Co-Cr-Mo) alloy for patients with sensitivities to certain metals.
    • Oxford® Cementless Partial Knee, the only FDA-approved cementless partial knee implant in the U.S. that has been shown to be efficient3,4 in the OR, and has been proven to have excellent longevity5,6 worldwide.
    • Persona® OsseoTi® Keel Tibia, a cementless anatomic tibia with a 3D printed porous tray from our clinically proven Persona Knee System5-7 designed to deliver stable initial and biological fixation and intra-operative versatility.8
    •  Persona IQ® 30 mm Stem, the world's only smart knee implant, now in a 30 mm stem length, that collects data directly from the knee to provide post-operative recovery insights9,10 and trends, allowing care teams to monitor and personalize the total knee arthroplasty patient experience9-11 with the goal of improving practice efficiency.12-15

    Upper Extremities Technology

    • OsseoFit™ Stemless Shoulder System, an anatomically shaped,16-18 asymmetric stemless shoulder implant designed for stable initial19-22 and biological fixation23, 24 by optimizing anatomic humeral fit for stemless shoulder arthroplasty.

    ASC Solutions

    • ZBX, Zimmer Biomet's new comprehensive ASC program offering surgeons an experienced partner to strategically incorporate solutions, unique to each surgeon's needs, providing efficiency in the OR and beyond.

    For more information about Zimmer Biomet events at AAOS 2025, visit www.zimmerbiomet.com/academy2025. 

    Important Safety Information for Oxford Cementless Partial Knee:

    The Oxford® Cementless Partial Knee System is indicated for use in unilateral knee procedures with osteoarthritis or avascular necrosis limited to the medial compartment of the knee. It is intended to be implanted without the application of bone cement for patients whose clinical condition would benefit from a shorter surgical time compared to the cemented implant. The Oxford Partial Knee Is not indicated for use in the lateral compartment or for patients with ligament deficiency, or for use in simultaneous bilateral surgery or planned staged bilateral procedures. Potential risks include, but are not limited to, loosening, dislocation, fracture, wear and infection, any of which can require additional surgery. For a full list of product indications, contraindications and warnings, please see the associated product Instructions For Use (IFU).

    About Zimmer Biomet

    Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. 

    With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

    For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.x.com/zimmerbiomet. 

    Cautionary Statement Regarding Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the Company's expectations, plans, intentions, strategies, prospects, business plans, product and service offerings, new product launches, potential clinical successes, and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

    References:

    1. Cardenas JM, Gordon D, Waddell BS, Kitziger KJ, Peters PC Jr, Gladnick BP. Does Artificial Intelligence Outperform Humans Using Fluoroscopic-Assisted Computer Navigation for Total Hip Arthroplasty? Arthroplasty Today. 2024 May 27;27:101410. doi: 10.1016/j.artd.2024.101410. PMID: 38840694; PMCID: PMC11150909.  
    2. Dilbone ES, Heimann AF, Leal J, Ryan SP, Wellman SS. Evaluating the Accuracy of a Computed Tomography-Based Mixed-Reality Navigation Tool for Acetabular Component Positioning in Total Hip Arthroplasty. The Journal of Arthroplasty. 2025.
    3. Pandit, H., et al. "Improved fixation in cementless unicompartmental knee replacement: five-year results of a randomized controlled trial." JBJS 95.15 (2013): 1365-1372.
    4. Stempin R, Kaczmarek W, Stempin K, Dutka J. Midterm Results of Cementless and Cemented Unicondylar Knee Arthroplasty with Mobile Meniscal Bearing: A Prospective Cohort Study. Open Orthop J. 2017 Oct 31;11:1173-1178. doi: 10.2174/1874325001711011173. PMID: 29290853; PMCID: PMC5721307
    5. NJR-UK. The National Joint Registry 21st Annual Report 2024 London, 2024 [Available from: https://reports.njrcentre.org.uk/Portals/0/PDFdownloads/NJR%2021st%20Annual%20Report%202024_Knees.pdf.
    6. AOANJRR. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2023 Annual Report Adelaide, AOA2024 [updated 2024. Available from: https://aoanjrr.sahmri.com/documents/10180/1798900/AOANJRR+2024+Annual+Report.pdf/9d0bfe03-2282-8fc8-a424-b8d9abb82b1f?t=1727666185313.
    7. American Joint Replacement Registry (AJRR): 2024 Annual Report. Rosemont, IL: American Academy of Orthopaedic Surgeons (AAOS), 2024. https://www.aaos.org/registries/publications/ajrr-annual-report/#:~:text=When%20citing%20any%20Annual%20Report,at%20RegistryEngagement%40aaos.org

      National Joint Registry of England, Wales, Northern Ireland, the Isle of Man and Guernsey. 20th Annual Report 2023
    8. Mueller JK, et al. Persona OsseoTi Keel Tibia Provides Stable Initial Fixation 4027.2-GLBL-en. November 2022
    9. Cushner FD, Yergler J, ElashoffB, Aubin PM, VertaP, Scuderi GR. Staying Ahead of the Curve: The Case for Recovery Curves in Total Knee Arthroplasty. The Journal of Arthroplasty. 2024;doi:10.1016/j.arth.2024.07.039
    10. Cushner FD, Sculco PK, Long WJ. The Talking Knee Is a Reality: What Your Knee Can Tell You After Total Knee Arthroplasty. J OrthopaedicExperience and Innovation. 2022;2022
    11. Cushner FD, Schiller P, Gross J, Mueller JK, Hunter W. A TOTAL KNEE ARTHROPLASTY PROSTHESIS CAPABLE OF REMOTE PATIENT MONITORING. OrthopaedicProceedings. 2021/06/01 2021;103-B(SUPP_9):18-18 doi:10.1302/1358-992X.2021.9.018
    12. Yocum DS, Redfern RE, Yergler JD. Delayed Recovery Following Total Knee Arthroplasty Identified by Remote Monitoring With Tibial Extension Sensors. Arthroplasty Today. 2023/10/01/ 2023;23:101188. doi: https://doi.org/10.1016/j.artd.2023.101188
    13. Yocum D, HousholderE, Yergler J. Manipulation under Anesthesia Following TKA with Persona IQ: A Case Series. J OrthopCase Rep. Aug 2023;13(8):127-131. doi:10.13107/jocr.2023.v13.i08.3844
    14. Dundon J, Aubin P, Hunter W. Objective Gait Analysis Following Total Knee Arthroplasty with a Smart Implant Directs Early Intervention with Manipulation under Anesthesia. Journal of OrthopaedicExperience & Innovation. 2024;Februarydoi:https://doi.org/10.60118/001c.89961.
    15. Parikh N, Redfern R, Yocum D, Andel D V, Yergler J. MT46 Patient Experience and Outcomes with Post-Surgical Remote Monitoring for Patients with Total Knee Arthroplasty (TKA). Value in Health. 2024/06/01/ 2024;27(6, Supplement):S290. doi:https://doi.org/10.1016/j.jval.2024.03
    16. Mueri, C, Snethen, K, Parisi, R, Son, Yang, Duquin, T Characterization of the Asymmetric Bone Envelope of the Proximal Humeral Metaphysis for Stemless Shoulder Implants. ORS Orthopaedic Research Society 2025 Annual Meeting, Paper No. 1175; 2025 Feb 7-11; Phoenix, Arizona.
    17. Son, Y, Mueri, C, Snethen, K, Bowman, L, Parisi, R, Duquin, T Optimizing Stemless Humeral Anchors: Asymmetrical Designs for Minimizing Cortical Bone Impingement while Maximizing Cancellous Bone Purchase. ORS Orthopaedic Research Society 2025 Annual Meeting, Paper No. 2051; 2025 Feb 7-11; Phoenix, Arizona.
    18. ZRR_WI_6743_24. Analysis of Potential Cortical Perforation for the OsseoFit Stemless Shoulder. Zimmer Biomet Internal Research Report on File.
    19. Snethen, K, Mueri, C, Kriska, T, Son, Y, Bandi, M The Sensitivity of the Stability of Stemless Humeral Implants to Surgical, Patient and Design Factors in Reverse Shoulder Arthroplasty. Presented at the ORS Orthopaedic Research Society Annual Meeting; 2023, Dallas, Texas.
    20. Snethen, K, Son, Y, Mueri, C, Bischoff, J The Effect of Press-fit on Initial Stability in Stemless Shoulder Arthroplasty. Presented at the ISTA International Society for Technology in Arthroplasty Annual Meeting; 2022, Maui, Hawaii.
    21. Snethen, K, Mueri, C, Son, Y, Parisi, R, Duquin, T The Effect of Geometric Design on Initial Stability of Stemless Shoulder Implants. ORS Orthopaedic Research Society 2025 Annual Meeting, Paper No. 1168; 2025 Feb 7-11; Phoenix, Arizona.
    22. ZBTR_30118. Anchor-Level Micromotion of the OsseoFit Stemless Shoulder with Application in Anatomic Total Shoulder Arthroplasty. Zimmer Biomet Internal Design Verification Report on File.
    23. Gupta, G Evaluation of Bony Ingrowth Implant Materials in an In Vivo Sheep Long Bone Defect Model 12-04/12-07, February 2013. 32.
    24. Gupta, G OsseoTi Porous Metal For Enhanced Bone Integration: an Animal Study. White Paper. 2014. Form No. BMET0718.0-GBL • REV1214.

    Laboratory and animal studies are not necessarily indicative of clinical performance.

    HipInsight™ System is a trademark of Surgical Planning Associates, Inc.

    Microsoft and HoloLens 2 are trademarks of the Microsoft Corporation.

    Persona IQ: The objective kinematic data generated by the Canary Canturio® Tibial Extension with CHIRP® System are not intended to support clinical decision-making and have not been shown to provide any clinical benefit.

    345 E. Main St.

    Warsaw, IN 46580

    www.zimmerbiomet.com    

    Media

    Investors

    Heather Zoumas-Lubeski

    David DeMartino

    445-248-0577

    646-531-6115

    [email protected]

    [email protected] 

    Kirsten Fallon

                   Zach Weiner

    781-779-5561

                   908-591-6955

    [email protected] 

                   [email protected]  

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-highlights-diverse-portfolio-of-orthopedic--musculoskeletal-innovations-at-aaos-2025-annual-meeting-302396091.html

    SOURCE Zimmer Biomet Holdings, Inc.

    Get the next $ZBH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZBH

    DatePrice TargetRatingAnalyst
    12/17/2024$125.00 → $128.00Neutral → Overweight
    Analyst
    9/10/2024Peer Perform
    Wolfe Research
    7/1/2024$140.00 → $115.00Overweight → Neutral
    Piper Sandler
    5/30/2024$129.00Neutral
    Goldman
    5/21/2024$150.00Hold → Buy
    Argus
    1/4/2024$135.00 → $125.00Outperform → In-line
    Evercore ISI
    10/20/2023$120.00Neutral
    ROTH MKM
    8/28/2023$139.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

      WARSAW, Ind., May 22, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 9:20 a.m. ET. A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer Biomet  Zimmer Biomet is a global medical technology leader with a comprehensive portfo

      5/22/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Announces First Quarter 2025 Financial Results

      First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basisFirst quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposalsWARSAW, Ind., May 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025.  The Company reported first quarter net sales of $1.909 billion, an increase of 1.1% ove

      5/5/25 6:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Completes Acquisition of Paragon 28

      Transaction Further Strengthens Company's Position in High-Growth Foot and Ankle Segment WARSAW, Ind., April 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"; NYSE and SIX: ZBH), a global medical technology leader, today announced it has completed the acquisition of Paragon 28, Inc. ("Paragon 28"), a leading medical device company focused exclusively on the fast-growing foot and ankle orthopedic space. "We look forward to building on the strong foundation set by Albert DeCosta and the Paragon 28 team and are excited to officially welcome them to the Zimm

      4/21/25 9:00:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Leadership Updates

    Live Leadership Updates

    See more
    • Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

      WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac

      3/6/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Appoints Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer

      WARSAW, Ind., Feb. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Jehanzeb Noor is joining the Company as Senior Vice President, Chief Strategy, Innovation and Business Development Officer. He will report to Ivan Tornos, President and CEO of Zimmer Biomet. In his new role, Mr. Noor will be responsible for leading strategy development and execution and all facets of M&A, including the integration for our pending acquisition of Paragon 28. In addition, he will have oversight of the research and

      2/27/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Announces Upcoming Changes to Company's Board of Directors

      WARSAW, Ind., Feb. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced upcoming changes to the Company's Board of Directors, including:  Non-Executive Chairman of the Board Christopher Begley will retire from the Board of Directors at the Company's annual meeting of stockholders on May 29, 2025, pursuant to the mandatory director retirement age in the Company's Corporate Governance Guidelines;President and CEO Ivan Tornos will become Chairman of the Board upon Mr. Begley's retirement; andMichael Farrell

      2/25/25 4:05:00 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zimmer Biomet upgraded by Analyst with a new price target

      Analyst upgraded Zimmer Biomet from Neutral to Overweight and set a new price target of $128.00 from $125.00 previously

      12/17/24 8:26:36 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Wolfe Research initiated coverage on Zimmer Biomet

      Wolfe Research initiated coverage of Zimmer Biomet with a rating of Peer Perform

      9/10/24 8:03:41 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Zimmer Biomet from Overweight to Neutral and set a new price target of $115.00 from $140.00 previously

      7/1/24 7:51:41 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      11/13/23 4:02:02 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Begley Christopher B bought $117,114 worth of shares (1,000 units at $117.11), increasing direct ownership by 39% to 3,540 units (SEC Form 4)

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      9/29/23 4:05:41 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Noor Jehanzeb

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      4/3/25 5:06:51 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Farrell Michael J.

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      4/2/25 8:40:00 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Begley Christopher B

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      4/2/25 4:11:50 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Financials

    Live finance-specific insights

    See more

    $ZBH
    SEC Filings

    See more
    • Zimmer Biomet Announces First Quarter 2025 Financial Results

      First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basisFirst quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposalsWARSAW, Ind., May 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025.  The Company reported first quarter net sales of $1.909 billion, an increase of 1.1% ove

      5/5/25 6:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Completes Acquisition of Paragon 28

      Transaction Further Strengthens Company's Position in High-Growth Foot and Ankle Segment WARSAW, Ind., April 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"; NYSE and SIX: ZBH), a global medical technology leader, today announced it has completed the acquisition of Paragon 28, Inc. ("Paragon 28"), a leading medical device company focused exclusively on the fast-growing foot and ankle orthopedic space. "We look forward to building on the strong foundation set by Albert DeCosta and the Paragon 28 team and are excited to officially welcome them to the Zimm

      4/21/25 9:00:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results

      WARSAW, Ind., April 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Monday, May 5, 2025, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do so by

      4/10/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form SD filed by Zimmer Biomet Holdings Inc.

      SD - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

      5/23/25 7:00:04 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zimmer Biomet Holdings Inc.

      SCHEDULE 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      5/6/25 4:46:12 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Zimmer Biomet Holdings Inc.

      10-Q - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

      5/5/25 4:00:26 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

      SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      11/14/24 1:22:34 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

      SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      11/13/24 1:44:56 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

      SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      2/14/24 10:02:59 AM ET
      $ZBH
      Industrial Specialties
      Health Care